Skip to content
type1.science
Phase 2RecruitingNCT05594563

TADPOL: DFMO/polyamine pathway in recent-onset T1D

Randomized phase 2 study testing difluoromethylornithine (DFMO), a polyamine-pathway drug, to reduce beta-cell stress and preserve remaining insulin production in recent-onset T1D.

Primary endpoints

  • Clinical efficacy of oral DFMO after 6 months
  • Treatment-related adverse events

Results so far

No results posted yet.